Pharma stocks face Q4 reality check amid global headwinds
Analysts expect modest revenue growth but pressure on profitability in the March quarter
Analysts expect modest revenue growth but pressure on profitability in the March quarter
Pharma and healthcare stocks stay in focus as investors track earnings, USFDA approvals, hospital growth, and global market pressures
Subscribe To Our Newsletter & Stay Updated